The FDA greenlit AstraZeneca’s anti-CTLA-4 antibody tremelimumab in combination with its checkpoint inhibitor Imfinzi as a treatment for patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.
https://www.pharmalive.com/wp-content/uploads/2021/10/AstraZeneca-Pays-560K-to-Settle-Race-Gender-Discrimination-Allegations-BioSpace-10-5-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-24 11:25:332022-10-24 11:25:33AstraZeneca’s Imjudo-Imfinzi combo scores FDA approval in liver cancer
